肝癌患者外周血CD4^＋／CD25^＋调节T细胞分析  

Analysis of CD4^＋/CD25^＋ regulatory T cells in peripheral blood in patients with primary hepatic carcinoma

作　　者：赵晓军[1] 刘英[1] 

机构地区：[1]河北省廊坊市人民医院,065000

出　　处：《中国医学创新》2009年第3期11-13,共3页Medical Innovation of China

摘　　要：目的探讨肝癌患者外周血CD4^＋／CD25^＋调节T细胞（Treg）水平的变化特点及其临床意义。方法采用流式细胞仪检测63例原发性肝癌患者和30例健康人外周血CD4^＋／CD25^＋调节T细胞水平，并进行水平比较和分层分析。结果肝癌组外周血CD4^＋／CD25^＋调节T细胞水平（14．06±2．34）％，明显高于健康对照组（6．05±1．57）％（P〈0．05）；外周血CD4^＋／CD25^＋调节T细胞水平与肝癌病理类型无相关性（P〉0．05）；与临床分期密切相关，Ⅰ＋Ⅱ期亚组（8．31±1．43）％与健康对照组比较差异无统计学意义（P〉0．05），而与Ⅲ期亚组（13．68±2．31）%、Ⅳ期亚组（18．50±2．98）％比较差异有统计学意义（P〈0．05）。结论肝癌患者外周血CD4^＋／CD25^＋调节T细胞水平明显升高，且与肿瘤的发生发展密切相关，可作为评估肝癌患者预后的一项指标。Objective To explore the character and clinical significance of CD4^＋/CD25^＋ regulatory T cells （Treg） in peripheral bloed in patients with primary hepatic carcinoma. Methods To detect the level of CD4^＋/CD25^＋ Treg with flow cytometry in the group of 63 cases of primary hepatic carcinoma and the control group of 30 cases of normal. The data was analyzed and compared between two groups. Results The primary hepatic carcinoma patients showed an obviously increasement of CD4^＋/CD25^＋ Treg, compared with the normal control group [ （ 14. 06 ± 2. 34 ） % vs （ 6.05 ± 1.57 ） % （ P 〈 0. 05） ]. There was no relation between CD4^＋/CD25^＋ Treg and pathological classification, but was closely related with clinical stage. There was no statistical difference between stage （ Ⅰ ＋ Ⅱ ） subgroup （8.31 ± 1.43 ） % and normal control group （P 〉 0. 05 ）, but obvious difference compared with stage III subgroup （ 13.68 ± 2. 31 ） % and stage Ⅳ subgroup （ 18.50 ± 2. 98） % （ P 〈 0. 05 ）. Conclusion It had been proved that the level of CD4^＋/CD25^＋ Treg in the peripheral blood was higher in the cases of primary hepatic carcinoma, and the CD4^＋/CD25^＋ Treg was related with the regression of tumor. It could be one of important indexes to evaluate the progression of primary hepatic carcinoma.

关 键 词：原发性肝癌 CD4^+/CD25^+调节T细胞 流式细胞技术 

分 类 号：R512.62[医药卫生—内科学] R779.65[医药卫生—临床医学]